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Sequential Alterations in Catabolic and Anabolic Gene
Expression Parallel Pathological Changes during
Progression of Monoiodoacetate-Induced Arthritis
Jin Nam1.¤, Priyangi Perera1., Jie Liu1, Bjoern Rath2, James Deschner3, Robert Gassner4, Timothy A.
Butterfield5, Sudha Agarwal1,6*
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Surgery, University of Innsbruck College of Medicine, Innsbruck, Austria, 5 Rehabilitation Sciences, College of Health Sciences, University of Kentucky, Lexington, Kentucky,
United States of America, 6 Department of Orthopedics, The Ohio State University, Columbus, Ohio, United States of America

Abstract
Chronic inflammation is one of the major causes of cartilage destruction in osteoarthritis. Here, we systematically analyzed
the changes in gene expression associated with the progression of cartilage destruction in monoiodoacetate-induced
arthritis (MIA) of the rat knee. Sprague Dawley female rats were given intra-articular injection of monoiodoacetate in the
knee. The progression of MIA was monitored macroscopically, microscopically and by micro-computed tomography. Grade
1 damage was observed by day 5 post-monoiodoacetate injection, progressively increasing to Grade 2 by day 9, and to
Grade 3–3.5 by day 21. Affymetrix GeneChip was utilized to analyze the transcriptome-wide changes in gene expression,
and the expression of salient genes was confirmed by real-time-PCR. Functional networks generated by Ingenuity Pathways
Analysis (IPA) from the microarray data correlated the macroscopic/histologic findings with molecular interactions of genes/
gene products. Temporal changes in gene expression during the progression of MIA were categorized into five major gene
clusters. IPA revealed that Grade 1 damage was associated with upregulation of acute/innate inflammatory responsive
genes (Cluster I) and suppression of genes associated with musculoskeletal development and function (Cluster IV). Grade 2
damage was associated with upregulation of chronic inflammatory and immune trafficking genes (Cluster II) and
downregulation of genes associated with musculoskeletal disorders (Cluster IV). The Grade 3 to 3.5 cartilage damage was
associated with chronic inflammatory and immune adaptation genes (Cluster III). These findings suggest that temporal
regulation of discrete gene clusters involving inflammatory mediators, receptors, and proteases may control the progression
of cartilage destruction. In this process, IL-1b, TNF-a, IL-15, IL-12, chemokines, and NF-kB act as central nodes of the
inflammatory networks, regulating catabolic processes. Simultaneously, upregulation of asporin, and downregulation of
TGF-b complex, SOX-9, IGF and CTGF may be central to suppress matrix synthesis and chondrocytic anabolic activities,
collectively contributing to the progression of cartilage destruction in MIA.
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At the onset of the disease, an etiologic agent or an insult/
trauma of the joint causes focal edema and minor surface erosion
in the cartilage. Progression of cartilage destruction is marked by
further fibrillation accompanied by loss of matrix and chondrocytes in the superficial layers of the cartilage. Proliferating
chondrocytes become apparent as cell clusters in the middle zone
of the cartilage. Further progression of fibrillation and cartilage
erosion leads to increased loss of cartilage matrix resulting in bone
denudation, the hallmark of osteoarthritic lesions. The rate of
disease progression and amount of joint damage is not predictable,
and varies among patients. However, the progression of joint
damage appears to follow a similar pattern and therefore can be

Introduction
Osteoarthritis (OA) is a debilitating joint disease, causing severe
pain and physical disabilities to millions of people worldwide
[1,2,3]. The etiopathology of OA is multifactorial. Chronic
inflammation, degeneration of the extracellular matrix and
abnormal remodeling of the underlying bone, all take part in
cartilage destruction [4,5,6,7]. Cartilage matrix is mainly composed of collagens and proteoglycans synthesized by chondrocytes
residing in the matrix. Collagens, mainly Type II, type IX and
type XI, provide the tensile strength, whereas proteoglycans rich in
water act as shock absorbents during cartilage loading.
PLoS ONE | www.plosone.org
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scattered subchondral bone lesions on the femoral condyles and
patellar groove (Figure 1l, Movie S3).
On day 21 post-monoiodoacetate injection (MIA21), increased
cartilage and bone damage in the patellar groove and ridges, fulldepth lesions and pits on the femoral condyles were observed
(Figure 1m–o). Histology revealed fissuring with matrix loss,
fibrocartilage formation within the denuded cartilage and
abnormal subchondral bone marrow intrusion typical of Grade
3 to 3.5 damage. Micro-CT imaging showed pitted areas of bone
loss on the femoral condyles and patellar groove (Figure 1p,
Movie S4).

categorized into various grades according to the extent of damage
in the cartilage and bone [8,9].
Chondrocytes take part in cartilage damage by synthesizing
catabolic cytokines and enzymes that breakdown the matrix as
well as impairing their ability to repair the matrix. Studies focusing
on the molecular events in human OA inception and progression
by genomic or proteomic profiling of intra-articular lesions have
revealed distinct gene profiles in OA specimens as compared to
visually unaffected cartilage [10,11,12,13,14,15]. Similarly, gene
association studies in large populations have identified a number of
genes that might confer susceptibility to OA [16,17,18,19].
However, the knowledge of the discrete molecular events that
support the time-dependent progression of OA remains incomplete.
In this study, we aimed to conduct a systematic longitudinal
examination of molecules and pathways associated with the
progression of cartilage damage. A widely used model of
monoiodoacetate-induced arthritis (MIA) of the rat knee was
utilized [20,21]. The progression of MIA was analyzed by
macroscopic, microscopic and micro-tomographic (mCT) analyses
and categorized into various stages of cartilage damage using the
grading system of Pritzker et al. [9]. A transcriptome-wide analysis
was conducted on the cartilage of temporally well-defined stages of
MIA and compared to those of sham control cartilage. Ingenuity
Pathways Analysis (IPA) was employed to obtain key insights into
molecular relationships and networks/mechanisms during the
progression of cartilage destruction. This analysis linked the
microarray data to relevant, manually curated information from
periodically updated knowledge databases in order to interpret the
global impact of differentially regulated molecules during MIA
progression. We believe that this study is the first to systematically
elucidate the longitudinal time-dependent gene regulation and
molecular networks/mechanisms throughout the course of MIA
progression and cartilage destruction.

Transcriptome-wide regulation of gene expression
during the progression of MIA
We next determined the changes in transcriptome-wide gene
expression profiles during the progression of MIA in the distal end
of femoral cartilages in Cont, MIA5, MIA9 and MIA21 rats
exhibiting Grade 0, Grade 1, Grade 2 and 3–3.5 cartilage damage,
respectively. Principal components analysis (PCA) revealed
relatively uniform distribution of overall gene expression among
the samples in each group (n = 3) except in MIA9 group, where the
overall gene expression was distributed between MIA5 and MIA21
(Figure 2A). Significant differences in gene expression over the
course of MIA progression were observed, as evidenced by the
average F ratio (signal to noise ratio) of 18.8.
Of the 27,342 transcripts detectable by Affymetrix GeneChips
array, 2,034 (7.44%) transcripts were significantly (p,0.05) and
differentially up- or downregulated at one or more time points by
more than two-fold change. In the hierarchical clustering analysis
of the differentially regulated genes (p,0.05, over 62-fold change),
distinct sets of genes were regulated at each stage of MIA
progression (Figure 2B). The most interesting information derived
from the hierarchical clustering was that: (i) as compared to Cont,
the maximal changes in gene expression occurred in MIA5,
judging by its farthest distance from Cont (Figure 2B), followed by
MIA21 and MIA9; and (ii) distinct individual sets of genes were
temporally either upregulated or suppressed during the progression of MIA.

Results
Macroscopic and microscopic changes in cartilage and
subchondral bone during the progression of MIA

Cluster analysis of major functional genes during the
progression of MIA

The progression of MIA was monitored by overall macroscopic
and microscopic changes at the distal ends of femurs (Figure 1).
The articular surface of Cont femurs exhibited normal cartilage
morphology, histology and bone imaging by mCT, typical of
Grade 0/healthy cartilage (Figure 1 a–d, Movie S1). The
progression of MIA followed the similar pathologies as described
by Guzman et al. [22]. Typically, femurs from MIA afflicted knees
exhibited greater extent of cartilage damage around the patellar
groove than on femoral condyles and intercondylar fossa (Figure 1
e, f, i, j, m, n). The examination of time-dependent progression of
knee cartilage damage showed that, on day 5 post MIA induction
(MIA5), femurs showed cartilage damage typical of Grade 1, i.e.,
superficial fibrillation, chondrocyte proliferation, clustering and
disorientation, and some loss of tidal ridge demarcation (Figure 1e–
g) [9,22]. Bone damage was not apparent microscopically or by
mCT imaging at both patellar and condylar surfaces (Figure 1e–h,
Movie S2).
Analysis of MIA9 cartilage revealed marked lesions at the apexes
of condyles and ridges of the patellar groove (Figure 1i–k). The loss
of the tidal layer and deeper lesions in some areas were observed.
Chondrocytes appeared larger, some with multiple nuclei and
disarrayed. Subchondral bone marrow extensions towards cartilage and deposition of fibrous tissue in the lesions typical of Grade
2 cartilage degeneration were apparent. The mCT images revealed
PLoS ONE | www.plosone.org

Among the 2,034 transcripts that were significantly up- or
downregulated during the progression of MIA, 1,971 were
unique genes annotated by Ensembl. These genes were then
analyzed by Davies-Bouldin index [23] to render optimal number
of clusters for partition clustering and were assigned to one of the
five trends of temporal gene regulation (Figure 3). The graphs
represent 10 most regulated genes in each cluster, and were
groups of genes that exhibited: peak-upregulation at day 5 after
MIA induction, followed by decrease in gene expression (Cluster
I ); peak-upregulation at day 9 after MIA induction (Cluster II );
gradual increase in gene expression that peaked at day 21 after
MIA injection (Cluster III ); peak-downregulation at day 5 after
MIA injection, followed by relative increase in gene expression
(Cluster IV ); and peak-downregulation at day 9 after MIA
induction (Cluster V ). Validation of at least two genes in each
cluster by rt-PCR exhibited similar trends in the differences in
gene expression as in microarray analysis (Figure 4). However, rtPCR technique being more sensitive contributed to greater fold
changes in gene expression as compared to the microarray
analysis.
Among the five distinct biologically functional gene clusters,
IPA identified three clusters mainly associated with inflammation
2

September 2011 | Volume 6 | Issue 9 | e24320

Gene Regulation during MIA Progression

Figure 1. Progression of MIA at the distal femoral ends by macroscopic, microscopic, and mCT analyses. Right knees of rats were given
an intra-articular injection of MIA on day 0, and distal ends of right femurs examined on post-injection days 5 (Grade 1 damage, MIA5), 9 (Grade 2
damage, MIA9) and 21 (Grade 3–3.5 damage, MIA21) and compared to saline-injected sham control (Cont). Macroscopic view of condyles, patellar
grooves of cartilage, histology, and subchondral bone imaging by mCT of: (a, b) Cont femur showing smooth surface, (c) normal histology and no
bone lesions on the femoral condyles and patellar grove and (d) lack of lesions in the subchondral bone (Movie S1); (e, f) MIA5 cartilage showing
superficial abrasions on the condyles (black arrows) and patellar groove (white arrows), (g) superficial fibrillation (black arrow), chondrocyte clustering
and disorientation (blue arrow), and (h) no bone lesions in mCT images (Movie S2); (i, j) MIA9 cartilage exhibiting lesions at the apexes of condyles
(black arrow) and ridges of the patellar groove (white arrow), (k) thinning of cartilage, matrix and cell loss above the tidal layer with large disarrayed
chondrocytes (black arrow), and some multinucleated chondrocytes (blue arrow), subchondral bone marrow/fibrous tissue extension in the cartilage
typical of Grade 2 damage (white arrow), and (l) scattered subchondral bone lesions on the femoral condyles and patellar groove in mCT images
(Movie S3); (m, n) MIA21 cartilage exhibiting increased lesions and damage on the condyles (black arrows) and patellar groove and ridges (white
arrow), (o) delamination of surface, full depth cartilage lesions and denuded cartilage layer at some places (black arrow), and (p) increased
subchondral bone lesions on the femoral condyles and patellar groove in mCT images (Movie S4). Each figure shows representative right femur from
separate rats from each group (n = 10). Arrows indicate cartilage damages. The distal ends of femurs showing 360u mCT projection can be found in
Movie files S1 to S4.
doi:10.1371/journal.pone.0024320.g001

and immunological disorders (Clusters I, II and III ), and the
remaining two clusters associated with musculoskeletal function
and disorders (Clusters IV and V ) (Figure 3, Table 1). To delineate
the overall functional relevance, the genes were further categorized into 7 functional sets: (i) Inflammation (cytokines, chemokines, and their receptors); (ii) Inflammation regulators (mediators,
transcription factors, and signaling molecules that regulate
inflammation); (iii) Cell division/proliferation; (iv) ECM (molecules
of the matrix); (v) ECM regulators (molecules that regulate matrix
synthesis and degradation); (vi) Growth factors (growth factors
and their receptors); (vii) Growth factor regulators (signaling
molecules and transcription factors that regulate growth factors)
(Figure 5, Tables 2, 3, 4, 5 and 6). Genes including molecules
involved in cell metabolism, transporters and ion channels, and
those with unknown functions were not included in the present
analysis. The genes in these Tables reflect: genes with known
function, the degree of gene regulation, and are in proportion to
the group of genes regulated in a particular cluster shown in
Figure 5.
PLoS ONE | www.plosone.org

Cartilage with Grade 1 damage (MIA5) exhibits gene
expression associated with innate immunity and cell
proliferation.
The cartilage with Grade 1 damage showed upregulation of
genes in Cluster I, and downregulation in Cluster IV. According to
IPA, the genes in Cluster I were functionally associated with
inflammation (116 genes; p-value 9.12E-09 – 1.80E-03) and
immunological diseases (103 genes; p-value 2.55E-09 – 1.80E-03)
(Table 1). The inflammation associated cytokine, chemokines and
their receptors significantly upregulated were Il1b, IL1rl1, Tlr7,
Ccr2, and Il-33. The major inflammation regulatory upregulated
genes were, C3ar1, Itgb2, -a2, -a4, Ptger4, various IgG Fc receptors
(Fcrls, Fcgr1a, Fcgr2a, Fcgr2b), molecules of the major histocompatibility complex (Hla-dmb, H2-Ea, cd74, Hla-dma, Rt-1ba) and
transcription factors Irf5, Irf8 (Table 2, Table S1) [24].
Interestingly, the genes associated with cell cycle/division/
differentiation such as Diap3, Anln, Prc1, Emb, Kif4, Kif23, Dusp6,
Vav1, Ccnb1, Ccna2, Ccnb2, Ccne1, Ccnf, and Cdk6 were also highly
upregulated (Table 2, Figure 5A, Table S1). The expression of
3
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Figure 2. Transcriptome-wide microarray analysis of cartilage from Cont, MIA5, MIA9, or MIA21 afflicted joints. (A) PCA analysis showing
reproducible overall gene expression in the articular cartilage from the right knee joint of 3 separate rats from Cont, MIA5, MIA9, or MIA21. (B) Overall
gene expression profiles of articular cartilage from 3 separate rats in each experimental group as compared to Cont. Hierarchical clustering
representing the transcripts that were significantly (p,0.05) and differentially up- or downregulated at one or more time points by more than twofold change. Note the maximal changes in overall gene expression occurred in MIA5, followed by MIA 21 and MIA9 as compared to gene expression
in cont cartilage.
doi:10.1371/journal.pone.0024320.g002

these genes paralleled the chondrocyte proliferation characteristically observed as disoriented clusters of chondrocyte distributed
in the cartilage (Figure 1g).
Despite the presence of cytokines like IL-1b and IL-33, genes for
several ECM proteins involved in cell-matrix attachment were
significantly upregulated in Grade 1 cartilage damage. These
genes included Vcan, Fbln2, and Spon1. Additionally, proteinases
with broad specificity involved in protein/matrix breakdown were
upregulated such as Hpse, Ctsc, Ctss, Arsb, and Plau (Table 2).
Strikingly, asporin, a suppressor of TGF-b/receptor interactions
was more than 9 fold upregulated in Cluster I [25]. Additionally,
genes for growth factors involved in cell division or immune
response such as, Fgf7, Csfrb, the regulators of Wnt signaling Sfrp1
and Sfrp2, were dynamically upregulated in cartilage with Grade 1
damage.

cytokines, Cytl1 [26], IL23r, and the inhibitor of osteoclastogenesis
Tnfrsf11b (osteoprotegerin), were major molecules suppressed,
along with several proinflammatory mediators Sod3, Alox12, and
Ptgds.
More importantly, a significant number of genes responsible for
proteoglycan synthesis and assembly were dramatically suppressed. These genes included Cilp (292 fold) and Cilp2 (222
fold), Fbln7, Fmod, Hapln3, Sdc4, Flnb, Chst3, Chst11, Acan, Cspg4,
Bgn, Spon2, Slf2, Hs6st2, and Eln. Surprisingly, at Grade 1 cartilage
damage, only collagens suppressed were Col27a1 and Col16a1
involved in calcification of cartilage and cell attachment,
respectively. In parallel, ECM regulatory genes revealed a
significant suppression of peptidase inhibitors and anabolic
enzymes such as Pi15, Serpina3a, and Timp3, likely accelerating
cartilage damage.
The scrutiny of global gene expression in cartilage with Grade 1
damage, also showed that several growth factors required for
cartilage growth/homeostasis were dramatically downregulated,
such as Gdf10, Ig f2, Ig fbp7, Bmp6, Fg frl1, Spock1, and Veg fa. Among
growth factor regulatory proteins the most suppressed genes were
Crim1, Sox9, Ltbp4, and htra, which may cumulatively retard
cartilage repair.

Cartilage with Grade 1 damage (MIA5) exhibits
suppression of genes associated with matrix synthesis
(Cluster IV)
In parallel to marked upregulation of genes in cartilage with
Grade 1 damage (MIA5, Cluster I ), several genes were significantly
downregulated and were assigned to Cluster IV. These genes were
associated with genetic disorders (163 genes, p-value 1.37E-06 –
2.08E-02) and musculoskeletal development and function (95
genes, p-value 2.10E-07 – 1.73E-02), and consisted of relatively
higher proportion of the genes for extracellular matrix and their
regulators (Figures 3D & 5D, Table 3, Table S2). Interestingly,
along with genes that induce cell division (Cluster I ), genes
associated with suppression of cell growth and apoptosis were
downregulated such as Scrg1 and Cidea in this cluster. Among
PLoS ONE | www.plosone.org

Major genes upregulated in cartilage with Grade 2
damage were associated with chronic inflammation
The Grade 2 cartilage damage showed upregulation of genes in
Cluster II, belonging to family of genes prevalent in genetic
disorders (116 genes, p- value 3.21E-10 – 6.79E-04) and
inflammatory response and immune trafficking (96 genes, p-value
4.81E-12 – 1.15E-03) (Table 1).
4

September 2011 | Volume 6 | Issue 9 | e24320

Gene Regulation during MIA Progression

Figure 3. Partition clustering of significantly regulated genes. Partition clustering analysis of the genes that showed two fold or greater
changes in their expression at one or more time points (p,0.05). The graphs represent 10 most regulated genes in each cluster. Identification of five
gene clusters that exhibited maximal upregulation on day 5 (Grade 1 damage) followed by their downregulation (Cluster I); upregulation on day 9
(Grade 2 damage) followed by their downregulation (Cluster II); upregulation in a sustained manner showing maximal expression on day 21 (Grade 3–
3.5 damage, Cluster III); downregulation of genes on day 5 followed by their upregulation (Cluster IV); and downregulation of genes on day 9
followed by their upregulation (Cluster V). Detailed description of these genes is given in Tables 1, 2, 3, 4, 5, and 6, and in Tables S1, S2, S3, S4, and S5.
doi:10.1371/journal.pone.0024320.g003

The major growth factors/receptors upregulated in cartilage
with Grade 2 damage were Pdgfb, Csfr1, and Igfbp3, Igfbp4, TGFbr1
and inhba. Additionally, several mediators of Wnt and Notch
signaling involved in bone formation were upregulated including,
Sfrp4, Wnt5a, and Wnt7b. (Table 4, Table S3) [24].

As compared to Grade 1, significantly fewer genes associated
with cell cycle/division were upregulated in Grade 2 cartilage
damage (Figures 3B & 5B, Table 4, Table S3). In fact, a number
of genes involved in the inhibition of cell division, Dapk1 and
Ccng1, were upregulated. The majority of genes significantly
upregulated in Grade 2 (Cluster II) were associated with chronic
inflammation such as chemokines and their receptor Ccl2, Ccl7,
Ccl9, Ccr1, Ccr5, Cx3cr1, and Cxcl16 as well as cytokines involved
in amplification of immune response Lif, Il7, Il18, and Ifngr2.
More notably, cytokines that induce bone resorption such as
Tnfsf11 (RANKL), Tnfrsf11a, Tnfrsf1B were significantly upregulated explaining the initiation of bone damage observed in m-CT
images (Figure 1l). In parallel, genes involved in the regulation of
inflammation were upregulated such as those associated with
clotting cascade, Tfpi2, adherence, Itgam, Itgax, Itga2, and NF-kB
signaling cascades Tank, Ripk2, NFkB2, NFkbie, Map2k3, and
enzymes necessary for the regulation of inflammation Pik3cb,
Dusp4, Ptpre, and Ptpn22.
Interestingly, the expression of genes for two matrix proteins,
Col5a3 and Sdc1 was significantly upregulated. Besides these, the
expression of genes associated with cartilage matrix degradation
was prevalent in the cartilage with Grade 2 damage (MIA9). These
genes were matrix metallopeptidase (MMP)-9, Mmp12, Mmp19,
Adamts4, Adamts7, Adamts12, Hyal1, Hyal3, Arsb, and Adam8.
Simultaneously, genes for inhibitors of proteases such as Timp1
and Serpine2 were also upregulated.
PLoS ONE | www.plosone.org

Major genes suppressed in the cartilage with Grade 2
damage were ECM and growth factor associated genes
During the progression of cartilage damage, we also observed
that a significant number of genes were downregulated in the
cartilage with Grade 2 damage (MIA9, Cluster V). Genes in Cluster
V, in parallel to Cluster II, were mainly matrix associated and
demonstrated maximal suppression on day 9, and associated with
genetic disorders (235 genes, p- value 1.87E-12 – 2.88E-02) and
skeletal and muscular disorders (134 genes, p-value 1.31E-10 –
2.88E-02) (Figures 3E &5E, Table 1).
There were several proinflammatory genes suppressed including
IL-7, IL-16 and IL-17b involved in amplification of immune
response, and Nrk in NF-kB signaling cascade (Table 5). Nevertheless,
the most dramatically suppressed gene was matrilin 3, a major
component of ECM, involved in the formation of filamentous
networks [27]. The expression of several collagens integral to cartilage
matrix such as collagens type -IXa1, -IIa1, -IXa2, -IXa3, -XIa1, XXIVa1, and -Va3 were significantly downregulated. The expression of other cartilage matrix components involved in cell-matrix and
5
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Figure 4. Confirmation of salient gene expression by rt-PCR. Quantitative rt-PCR analyses of specific transcripts of genes from articular
cartilage obtained from Cont, MIA5, MIA9, or MIA21. Two genes from Cluster I (A; Ctss and Il1b), Custer II (B; Mmp12 and Ccr1), Cluster III (C; Alox5 and
Vcam1), Cluster IV (D; Cilp and Sox9), and Cluster V (E; Col9a1 and Col2a1) were analyzed to verify the data obtained by microarray analysis (n = 5,
* p,0.05 as compared to Cont, ** p,0.01 as compared to Cont, # p,0.05 as compared to MIA5, ## p,0.01 as compared to MIA5, { p,0.05 as
compared to MIA9, {{ p,0.01 as compared to MIA9, { p,0.05 as compared to MIA21, {{ p,0.01 as compared to MIA21).
doi:10.1371/journal.pone.0024320.g004

matrix-matrix adhesion were suppressed such as Chad, Scin, Hapln1,
Vit, Mgp, and Fbln5 (Table 5, Table S4) [24]. Additionally, gene
expression of several molecules involved in collagen, chondroitin and
hyaluran synthesis were suppressed (Adamts3, Adamts6, Chsy3, Has2) as
well as those involved in mineralization (Alpl ).
The growth factors and their receptors and regulatory genes
suppressed in the cartilage with Grade 2 damage (MIA9) were
Omd, Ctg f, Bmp5, Bmp3, Tg fb3, Eg f, Ig fbp5, Fg fr2, Fg fr3, Ghr,
Tg fbr3, Bmpr1a, and Vdr. Strikingly, frizzeled related protein (Frzb)
was 52.7 fold suppressed along with other Wnt signaling molecules
(Wif1, Sfpr5, Fzd9, and Wisp3), and those involved in cartilage/
bone development (Ptch1, Ihh, Sox6, and Dlx5) (Table 5, Table S4)
[24].

Among the inflammatory genes, those involved in the regulation
of T and B cell functions Cxcl13, IL15, and suppression of
inflammation such as Il10rb, Lilbr4, Nfkbia, Socs3, and Pld2 were
simultaneously upregulated. Additionally, genes involved in LPS
responses and acute inflammation such as Tlr4, Lbp, F3, Alox5, Lpl,
and Ptges were upregulated.
In cartilage with Grade 3–3.5 damage, many ECM proteins
involved in bone repair/remodeling were upregulated such as Tnn,
Postn, and Lum, and collagens frequently associated with soft tissue
and wound repair (collagens type XVIIIa1, -IVa1, -IVa2, -IIIa1,
-XIIa1, -Va1, -VIa3), exhibited increased expression. Additionally, Adam23, Serpine1, Timp2, Mmp14, Mmp11, Mmp2, Ctsd, and
Adamts2 involved in ECM regulation during wound repair were
also significantly upregulated. The growth factors and their
regulators upregulated were Tgfb2, Ogn, Pdgfrb, and Egfr that are
all involved in cell growth and differentiation. Additionally,
signaling molecules associated with Wnt signaling were upregulated such as Wisp2, Notch3, and Acvrl.
Interestingly, we also observed that several of the ECM
associated proteins that were suppressed in Grade 2 cartilage
damage, were relatively upregulated in cartilage with Grade 3–3.5
damage. For example, Col2a1, 50.3-fold downregulated in
cartilage with Grade 2 damage, was only 9.06-fold suppressed in
Grade 3–3.5 damage. Similar upregulation of ECM associated
genes in Grade 3–3.5 damage relative to lesser damaged cartilage
included Matn3, Col10a1, Col9a1, Col9a3, Col11a2, Col11a3, Col5a3,

Major genes upregulated in cartilage with Grade 3–3.5
damage were associated with immune adaptation and
matrix modeling/remodeling
According to IPA, the specimens exhibiting Grade 3–3.5
cartilage damage (MIA21, Cluster III), were associated with those
generally found in skeletal and muscular disorders (131 genes, pvalue 1.47E-08 – 1.59E-03) and inflammatory diseases (124 genes,
p-value 6.71E-08 – 1.81E-03) and showed sustained and successive
upregulation in cartilage from Grade 1 to Grade 3–3.5 damage
(Figures 3C & 5C, Table 1). Interestingly, at this stage genes that
regulate apoptosis or inhibit cell division were upregulated, such as
Cdkn1a, Ccnd1, Pawr, Bcl2l11, and Klf10 (Table 6, Table S5).
PLoS ONE | www.plosone.org
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Table 1. IPA analysis showing top biological functions of each gene cluster at various stages of cartilage destruction in MIA.

Cartilage damage

Cluster

Name

p-value

Genes (#) associated

Grade 1 (MIA5)

I

Inflammation

9.12E-09 – 1.80E-03

116

Immunological Disease

2.55E-09 – 1.80E-03

103

Genetic Disorder

1.37E-06 – 2.08E-02

163

Skeletal and Muscular
Development and Function

2.10E-07 – 1.73E-02

95

Genetic Disorder

3.21E-10 – 6.79E-04

116

Inflammatory Response

4.81E-12 – 1.15E-03

96

Genetic Disorder

1.87E-12 – 2.88E-02

235

Skeletal and Muscular Disorders

1.31E-10 – 2.88E-02

134

Skeletal and Muscular Disorders

1.47E-08 – 1.59E-03

131

Inflammatory Disease

6.71E-08 – 1.81E-03

124

IV

Grade 2–2.5 (MIA9)

II

V

Grade 3–3.5 (MIA21)

III

doi:10.1371/journal.pone.0024320.t001

Scin, Sdc1, Hapln1, Vit, Prg4, Matn1, and Fbln5. The expression of a
number of growth factors and signaling molecules markedly
suppressed in Grade 2 damage were also relatively upregulated in
cartilage with Grade 3–3.5 damage. These growth factors were
associated with both cartilage and bone damage such as Omd,
Fgfr2, Fgfr3, Ctgf, Bmp5, Bmp3, Igfbp5, Egf, Frzb, Ptch1. Wif1, Sfrp5,
Sox6, Wisp3, and Dlx.

proteoglycans/collegens, directly or via activating intermediary
molecules in Cluster IV (Figure 6B).
The IPA of genes upregulated in cartilage with Grade 2
damage, revealed a molecular network (score 34) involved in
chronic inflammation, immune cell trafficking and perpetuation of
inflammatory response (Cluster II, Figure 7A). This network
appeared to be activated by TNF receptor and may invoke the
activities of the NF-kB signaling cascade, RIPK2, a potent
activator of NF-kB and inducer of apoptosis and chemokines. The
activation of NF-kB complex in turn may play a central role in
upregulating the expression of MMPs that cleave matrix proteins,
chemokines that attract immune cells, and Cd44 that mediates cell
adhesion/migration via hyaluronate/matrix attachment. Similarly, based on the existing role of chemokines, their upregulation
may further augment activity/gene expression of chemokines and
their receptors, such as Ccl7, Ccl9, Ccl13, Ccr1, Ccr5 and Pf4 (Cxcl4)
that are important for amplification of immune response and
recruitment of immune cells to the site of inflammation.
Simultaneous with persistent inflammation in the cartilage with
Grade 2 damage, the suppression of genes involving matrix
synthesis in Cluster V was observed (score 39, Figure 7B). IPA
network analysis suggested that the major foci of the molecular
network suppressed were TGF-b complex, Ig fbp, Ctg f and Eg f.
Suppression of these genes may have downregulated matrix
proteins such as collagens (-type II alpha-1, -type X alpha1, -type
XI alpha-1 and -2), and molecules involved in matrix synthesis
such as Adamts3 and Hapln1 (stabilizes cartilage matrix). More
importantly, a significant suppression of TGF-b complex in this
network may have also downregulated many genes associated with
bone formation such as Bglap, Dlx5, Alpl, and Bmpr1. The
downregulation of these genes during chronic inflammation may
result in the failure of matrix repair, thus accelerating the damage.
In the major molecular network in Cluster III (score 29,
Figure 8A), related to pathologies observed in Grade 3–3.5
cartilage damage, many of the genes were associated with immune
suppression and adaptation such as Socs3, Osmr, Gas7 and Il10rb
[28]. Interestingly, at this stage, except for IL-15, the upregulation of other inflammation-associated genes such as NF-kB
complex, IL-1 complex, IFN alpha and IFN beta complex,
MHC complex, and IL-12, was not evident. However, several
genes that are associated with B cell, T cell and macrophage
proliferation, differentiation, and migration, such as complement
cascade (innate immunity and macrophage activation), IL-15
(stimulates T-lymphocyte proliferation), and interferon-induced

Major molecular networks involved in cartilage damage
during the progression of MIA
We next subjected genes in individual clusters to IPA to
generate major functional molecular networks (Figures 6, 7 and 8).
The significance and specificity of IPA-generated networks were
based on the score of each network. The high score numbers
signified that gene networks are extremely specific to each cluster.
For example, a score of 43 of the molecular network in Cluster I
(Figure 6A) indicates that there is only a 1 in 1043 chance of getting
a network containing the same member of Network Eligible
molecules, when same numbers of molecules are randomly picked
from the IPA knowledge base.
The molecular network maximally upregulated in the specimens with Grade 1 cartilage damage (MIA5) were (i) acute
inflammation and (ii) cell cycle/cell division-related genes in Cluster
I. Genes that typically regulate innate immunity directly or via
activation of other mediators formed this network. For example,
IL-1b, which auto-regulates its own expression, may also
upregulate expression of Ccr2, Trem2 (stimulates production of
cytokines and chemokines in macrophages), IL10ra (receptor of IL10), Ptgfr, Cyba and Cybb (phagocytic oxidases that generate
superoxide), and NCF1 and -2 (oxidases that produce superoxides)
(Figure 6A). Strikingly, the genes associated with cell cycle
including Vav1, Emb, Prc1, Kif4A, Kif23, Kif20A, and Dock2 were
also prevalent in this network despite the presence of inflammation
(Figure S1).
Interestingly, in parallel to upregulation of genes associated with
innate immunity and cell cycle in Cluster I, other pathways were
simultaneously suppressed as observed in the major molecular
network for the Cluster IV (score 32, Figure 6B). For example,
asporin, an inhibitor of TGF-b [25] and a member of Cluster I, was
considerably upregulated at this stage of cartilage damage, and
may be responsible for preventing activation of TGF-b complex,
consequently downregulating matrix proteins and growth factors
such as Sox9, alkaline phosphatase, aggrecan, Cilp, Cilp2, and other
PLoS ONE | www.plosone.org
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Figure 5. Distribution of genes in each cluster according to their functions. Relative distribution of genes in each cluster subdivided
according to their functions. Cell division, genes involved in cell division, proliferation, apoptosis; Growth factors, genes for growth factors and their
receptors; GF reg, growth factor regulatory molecules and transcription factors; Inflammation, cytokines, chemokines and their receptors; Inflam reg,
inflammatory mediators, signaling molecules, transcription factors, and regulators; ECM, extracellular matrix proteins; ECM reg, Proteases, regulators
of ECM synthesis and breakdown; Others genes involved in cell metabolism, transporters and ion channels and genes of unknown function (Tables
S1, S2, S3, S4, and S5).
doi:10.1371/journal.pone.0024320.g005

models cannot depict arthritis exactly to humans, as the joint
mechanics differ in small quadrupeds [33].
The foremost findings from the transcriptome-wide gene expression profiles are that the MIA afflicted cartilage showed stage specific
reproducible changes in gene expression, as demonstrated by the
hierarchical and partition clustering analyses. Strikingly, MIA
progression involves up- or downregulation of approximately
7.44% of the transcripts by more than two-fold, at one or more
time points (p,0.05). Furthermore, discrete sets of genes at each stage
of cartilage damage appear to maximally regulate set of genes
associated with inflammation and ECM degradation.
The overall gene expression profiles and the IPA derived from
these profiles suggest that Grade 1 cartilage damage is likely
associated with upregulation of genes required for: (i) acute
inflammation/innate immunity such as superoxides, complement
components, integrins, IL-1/IL-1r, chemokines and their receptors,
and monocyte activating factors; (ii) chondrocyte-matrix interactions, i.e., versican, fibulin and microfibril; (iii) cleavage of matrix
and cell associated proteins such as broad specificity proteases
cathepsins and heparanase [34]; and (iv) cell proliferation such as
cell cycle/proliferation and mitogenic growth factors (FGF7 and
CSF receptor b). The presence of proliferating cells may support
increased cell division in the cartilage with Grade 1 damage
(Figure 1g). In parallel, suppression of genes essential for: (i)
proteoglycan synthesis/assembly, i.e., Cilp and Cilp2, Acan, Bgn, Eln,
Sdc2 and cell-matrix adhesion such as Col XVI 1a, and ColXVII
1a; and (ii) inhibitors of peptidases (Timp3, Serpina3, Pi15), may
further support increased proteolytic breakdown of cartilage matrix.
More importantly, upregulation of asporin that mediates downreg-

transmembrane protein 3 (Ifitm3, mediates cellular immunity)
were upregulated.

Discussion
To the best of our knowledge, this study documents the first
evidence of temporally controlled global gene regulation and
identifies the major determining molecular networks that likely
control the progression of cartilage damage in a well-established rat
model of MIA. We examined changes in the gene expression
profiles by transcriptome-wide microarray analysis in relation to the
progression of MIA determined by macroscopic, microscopic, and
mCT imaging to assess bone involvement [22,29,30,31]. This model
of experimental OA was considered useful due to its similarities to
the pathogenesis of OA, reproducibility, reasonable duration of the
test period, and ability to induce cartilage damage without
confounding effects of surgical wounding on the joint tissues
[21,22,29]. In this experimental model, the first 3 weeks of MIA
progression showed major changes in the cartilage destruction and
Grade 6 damage is achieved over a period of 8 weeks (56 days) [22].
After 3 weeks of MIA progression, the cartilage loss is slowly
replaced by fibrocartilage and bone. Therefore, we have focused on
the initial period of 3 weeks (21 days) where the cartilage damage
advanced to Grade 3–3.5. Although the progression of MIA in this
model was much faster, it exhibited a sequential progression of
cartilage damage observed over a longer period of time in other
models of OA. Furthermore, as described earlier, less than 2% cell
death was observed due to the monoiodoacetate-induced injury on
day 1 after monoiodoacetate injection [32]. Nevertheless, rodent
PLoS ONE | www.plosone.org
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Table 2. Induction of salient genes in cartilage with Grade 1 damage (Cluster I).

Cluster I (421 annotated genes, 267 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA5

OA9

Diap3

Diaphanus homolog 3; cytokinesis

CD

4.60

3.36

OA21
2.25

Anln

Anilin; cytokenesis

CD

4.42

3.37

1.76

Emb

Embigin; protein tyrosine phosphatase receptor type N

CD

4.09

4.00

2.00

Kif4

Kinesin Family member 4; microtubule-based motor proteins involved in cell division

CD

3.72

2.08

1.16

Kif23

Kinesin Family member 23; microtubule-based motor proteins involved in cell division

CD

3.56

2.09

1.30

Prc1

Protein regulator of cytokinesis 1; cytokinesis

CD

3.34

2.43

1.67

Dusp6

dual specificity phosphatase; mitogenic signal transduction via Erk and Map kinases

CD

3.28

3.41

2.88

Vav1

Vav Guanine nucleotide exchange factor; cell division and differentiation

CD

3.08

2.61

1.69

Ccnb1

Cyclin B1; cell cycle regulation

CD

2.95

2.10

21.13

Ccne1

Cyclin E1; cell cycle regulation

CD

2.63

1.50

1.02

Il1rl1

IL-1 receptor-like 1

Inf

8.60

3.50

2.11

Tlr7

Toll-like receptor 7; LPS receptor

Inf

5.06

2.74

3.23

Irf8

Interferon regulatory factor 8; regulate growth and differentiation

Inf

2.49

1.04

21.02

Ccr2

Chemokine (C-C motif) receptor; cell migration

Inf

2.30

2.06

1.02

Il1b

Interleukin 1 beta; inflammation

Inf

2.22

2.0

1.54

Il33

IL-33; neutrophil migration

Inf

2.00

21.02

1.15

C3ar1

complement 3a receptor 1; inflammation regulation

Inf2

4.92

3.18

3.72

Hla-dmb

Major histocompat complex, class II DM-b

Inf2

4.65

2.93

2.24

Ptger4

Prostaglandin E receptor 4; level and stability of cyclooxygenase-2

Inf2

4.55

2.81

2.43

Fcgr1a

Fc fragment of IgG receptor 1a (CD64); immune response

Inf2

4.26

3.03

3.00

Itgb2

Integrin beta 2; cell adhesion

Inf2

4.10

4.18

3.43

Itgal

Integrin alpha L; cell adhesion

Inf2

3.84

3.41

2.29

Vcan

Versican; connects cells to ECM, cell motility/division

ECM

9.09

7.95

6.35

Fbln2

Fibulin 2; ECM protein cell differentiation

ECM

6.55

4.12

2.87

Spon1

Spondin 1; cell adhesion protein

ECM

2.92

2.26

2.56

Aspn

Asporin; negative regulator of TGF-b

ECM2

9.33

5.77

8.38

Hpse

Heparanase; cleaves polymeric heparan sulfate molecules

ECM2

6.42

3.60

3.30

Ctss

Cathepsin S; activates serine proteases

ECM2

3.91

3.21

3.68

Arsb

Arylsulfatase b; hydrolyzes sulfate groups on chondroitin sulfate and dermatan sulfate

ECM2

3.75

3.70

2.62

Ctsc

Cathepsin C; cystein proteases/elastase

ECM2

3.72

3.66

3.29

Plau

Plasminogen activator, urokinase; serine protease, promotes fibrinolysis

ECM2

2.87

2.79

1.62

Fgf7

Fibroblast growth factor 7; growth of keratinocytes

GF

2.89

21.01

1.14

Csfrb

Colony stimulating factor receptor b; hematopiesis, immunological defense, bone metabolism

GF

2.76

2.14

1.54

Sfrp2

Secreted Frizzled related protein 2; Wnt signaling

GF2

4.04

21.06

3.05

Sfrp1

Secreted Frizzled related protein 1; Wnt signaling

GF2

3.59

3.07

1.94

CD, genes involved in cell division, proliferation, apoptosis; Inf, cytokines, chemokines and their receptors; Inf2, inflammatory mediators and their receptors, signaling
molecules, transcription factors, and regulators; ECM, extracellular matrix proteins; ECM2, Proteases, regulators of ECM synthesis and breakdown; GF, genes for growth
factors and their receptors; GF2, growth factor signaling molecules, transcription factors. A full list of these genes is given in Table S1.
doi:10.1371/journal.pone.0024320.t002

ulation of TGF-b activity, and consequently suppression of Sox9
may be responsible for the dramatic suppression of the above
proteoglycan-associated genes. Interestingly, genes such as asporin,
IL-1b, IL-1 receptor-like 1, cathepsin S, PGE receptor (EP4) and
integrins are also upregulated in OA in humans and experimental
animals, suggesting their possible role in the early stages of the
disease progression [35,36,37,38,39,40,41,42].
The most dramatic matrix breakdown and deficit in ECM
synthesis might occur in cartilage with Grade 2 damage. Overall,
the gene regulation in cartilage with Grade 2 damage was focused
around: (i) Chronic inflammation (chemokines and their receptors)
PLoS ONE | www.plosone.org

and the NF-kB signaling cascade, which not only regulates
inflammation and apoptosis, but also matrix degradation [43];
and (ii) Matrix breakdown, via increased expression of metalloproteases (MMP-9, -12, and -19, ADAMTS4, ADAMTS 7, ADAMTS
12, Hyal1, Hyal3) primarily responsible for cleaving collagens and
proteoglycans. In parallel suppression of genes associated with: (i)
ECM such as matrilin-3 and -1, major collagens (type IIa1, -Xa1,
-IXa1, -IXa2, -IXa3, -XIa1, -XIa2), Chad, Prg4; (ii) matrix
synthesis/assembly (Adamts3, Adamtsl3, Hs3stb1, Hs3st1, Chsy3,
Has2, Arsg, Alpl); (iii) growth factors and their receptors (Omd, Fg fr2,
Fg fr3, Ctg f, Bmp5, Ghr, Bmp3, Bmpr1a, Eg f ); and (iv) signaling
9
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Table 3. Suppression of salient genes in cartilage with Grade 1 damage (Cluster IV).

Cluster IV (312 annotated genes, 203 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA 5

OA 9

OA 21

Scrg1

stimulator of chondrogenesis 1; suppresses cell growth but induces chondrogenic differentiation

CD

261.6

253.8

212.2

Cidea

cell death-inducing DFFA-like effector a; activates apotptosis

CD

22.66

21.76

22.01

Cytl1

cytokine-like 1; likely involved in proteoglycan synthesis

Inf

253.6

247.5

249.8

Tnfrsf11b

TNFr superfamily, member 11b (OPG); inhibits osteoclastogenesis

Inf

29.03

28.75

24.40

Il23r

interleukin 23 receptor; JAK-STAT signaling

Inf

22.56

22.12

21.46

Sod3

superoxide dismutase 3, extracellular; antioxident enzymes

Inf2

27.41

23.89

22.42

Alox12

arachidonate 12-lipoxygenase; proliferative, antiapoptotic and proangiogenic

Inf2

22.53

22.27

22.77

Ptgds

PGD2 synthase;, smooth muscle contraction/relaxation, inhibition of platelet aggregation

Inf2

22.09

22.07

22.00

Cilp

cartilage intermediate layer protein; cartilage matrix protein

ECM

292.3

266.2

223.2

Cilp2

cartilage intermediate layer protein 2; cartilage matrix protein

ECM

221.9

219.2

23.31

Fbln7

fibulin 7; takes part in cell binding

ECM

213.3

29.92

23.71

Fmod

Fibromodulin; ECM assembly

ECM

213.1

211.9

21.75

Hapln3

Hyaluronan-proteoglycan link protein 3; proteoglycan link protein 3

ECM

26.50

26.13

26.03

Col27a1

collagen, type XXVII, alpha 1; involved in calcification of cartilage

ECM

24.57

23.24

23.30

Acan

aggrecan; major cartilage matrix protein

ECM

24.12

23.30

22.05

Cspg4

chondroitin sulfate proteoglycan 4; cartilage matrix protein

ECM

23.07

22.73

21.71

Spon2

spondin 2; extracellular matrix protein

ECM

22.89

2.23

1.73

Col16a1

collagen, type XVI, alpha 1; cell attachment

ECM

22.69

21.53

21.29

Eln

Elastin; part of ECM

ECM

22.59

1.05

1.51

Sdc4

syndecan 4; proteoglycan cell interactions

ECM

22.27

21.01

21.36

Bgn

biglycan; cartilage matrix protein

ECM

22.12

21.69

1.07

Col14a1

collagen, type XIV, alpha 1; fibrillar collagen

ECM

22.07

21.19

3.92

Pi15

peptidase inhibitor 15; serine protease inhibitor

ECM2

218.0

217.9

24.74

Chst3

chondroitin 6 sulfotransferase 3; chondroitin sulfate biosynthesis

ECM2

210.8

27.17

24.65

Serpina3

serpin peptidase inhibitor, clade A mem 3; anti-trypsin activity

ECM2

210.8

21.85

21.62

Chst11

Chondroitin-4 sulfotransferase 11; chondroitin sulfation

ECM2

24.71

24.25

24.88

Timp3

TIMP metallopeptidase inhibitor 3; inactivates MMPs

ECM2

22.87

1.14

1.31

Sulf2

sulfatase 2; sulfation of proteoglycans

ECM2

22.44

1.06

1.45

Hs6st2

heparan sulfate 6-O-sulfotransferase 2; heparan sulfate synthesis

ECM2

22.07

21.91

22.02

Gdf10

growth differentiation factor 10; Growth and differentiation

GF

222.6

216.6

24.89

Igf2

insulin-like growth factor 2; mitogenic

GF

27.05

26.48

24.87

Bmp6

bone morphogenetic protein 6; cartilage and bone formation

GF

25.96

25.40

23.56

Fgfrl1

fibroblast growth factor receptor-like 1; cell proliferation

GF

25.06

24.63

23.44

Spock1

sparc/osteonectin; inhibits cell-cycle and influences ECM synthesis

GF

23.01

22.76

23.02

Vegfa

vascular endothelial growth factor A; angiogenesis

GF

22.57

21.13

21.09

Crim1

cys rich transmembrane BMP regulator 1; BMP regulator 1

GF2

212.7

210.8

28.59

Sox9

SRY-box 9; transcription factor for chondrogenesis

GF2

210.2

29.70

25.59

Htra4

HtrA serine peptidase 4; suppresses IGF and TGF-b signaling

GF2

210.0

24.49

2.18

Igfbp7

IGF binding protein 7; stimulates PGI2 secretion, and cell adhesion

GF2

23.19

22.15

21.10

Fzd8

frizzled homolog 8 (Drosophila); Wnt signaling

GF2

23.15

22.15

1.10

Ltbp4

latent TGFb binding protein 4; TGF-b regulation

GF2

22.86

21.68

1.22

Please see Table 2 for group description. A full list of these genes is given in Table S2.
doi:10.1371/journal.pone.0024320.t003

molecules (Frzb, Lect1, Sfrp5, Fzd9, Sox6, Wisp3, Dlx5, Mad3, Smad9)
may further suppress cartilage and bone formation in these
advanced lesions. Our findings further confirm earlier studies
where significant upregulation of MMPs, ADAMTS4, arachidonate-5-lipoxygenase, and IL-18 was observed in both human and
experimental OA [10,12,13,15,39,44,45,46,47,48,49,50].
PLoS ONE | www.plosone.org

Interestingly, cartilage with Grade 3–3.5 damage showed
successive upregulation of genes from Grade 1 to Grade 3–3.5,
and those genes were involved in: (i) inflammation and immune
adaptation via relative downregulation of proinflammatory
molecules IL-1, TNF, NF-kB signaling; (ii) suppression of
inflammation (Socs3, Il10rb, Lilbr4, C1s, Nfkbia); (iii) LPS/
10
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Table 4. Induction of salient genes in cartilage with Grade 2 damage (Cluster II).

Cluster II (430 annotated genes, 305 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA 5

OA 9

OA 21

Dapk1

death-associated protein kinase 1; programmed cell death

CD

2.95

4.06

3.13

Ccng1

cyclin G1; cell cycle

CD

1.84

2.23

1.67

Ccl9

chemokine (C-C motif) ligand 9; bone resorption

inf

4.65

14.7

5.41

Ccr1

chemokine (C-C motif) receptor 1; immune cell recruitment

inf

4.53

10.7

5.43

Tnfsf11

TNF superfamily, memb 11 (RANKL); bone resorption

inf

1.98

9.52

6.04

Ccl7

chemokine (C-C motif) ligand 7; immune cell recruitment

inf

4.08

6.88

2.30

Lif

leukemia inhibitory factor; acute phase protein synthesis

inf

3.06

5.87

2.84

Ccl2

chemokine (C-C motif) ligand 2; chemoattraction migration of cells

inf

3.09

4.89

3.21

Il18

interleukin 18 (IFNg-inducing factor); macrophage activation

inf

3.63

4.23

3.69

Tnfrsf11a

TNF receptor mem 11a; NFkB activator, osteoclastogenesis

inf

3.01

3.73

2.71

Ccr5

chemokine (C-C motif) receptor 5; migration of immune cells

inf

3.27

3.59

2.60

Tnfrsf1b

TNF rec fam mem1B; ligand for OPG/RANKL, osteoclastogenesis

inf

2.81

3.30

2.37

Il7

Interleukin-7; amplification of immune response

inf

1.9

2.35

2.00

Ifngr2

Interfero receptor 2; amplification of immune response

inf

1.8

2.25

1.71

Tfpi2

tissue factor pathway inhibitor 2; inhibits blood coagulation

inf2

5.68

8.02

3.27

Pik3cb

phosphoinositide-3-kinase, b-polypep; immune cell activation

inf2

4.36

7.04

5.29

Dusp4

dual specificity phosphatase 4; negative regulator of cell prolif.

inf2

3.43

6.99

3.27

Itgam

integrin, alpha M (C3 receptor 3); C3 receptor 3

inf2

5.47

5.92

3.82

Itgax

integrin aX (C 3 receptor 4 subunit); C3 receptor4

inf2

3.45

5.68

3.22

Ptpre

Protein tyrosine phosphatase, receptor E; cell growth and different.

inf2

2.39

5.59

2.80

Ptpn22

Protein tyr phosphate; T cell regulation

Inf2

2.51

4.07

2.91

Cx3cr1

chemokine (C-X3-C motif) recept ‘1; immune cell regulation

inf2

2.85

3.84

2.92

Tank

TRAF family member,;NFkB activator

inf2

2.50

3.79

3.03

Cxcl16

chemokine (C-X-C motif) ligand 16; immune response

inf2

3.15

3.69

3.01

Ripk3

receptor-interact ser-thr kinase 3; NFkB signaling

inf2

3.33

3.58

2.51

Itga2

Integrin a2; receptor for collagens, fibronectin and cadherin

inf2

1.74

3.19

2.41

Nfkbie

NFkB polypeptide e; negative regulator of NFkB signaling

inf2

1.83

2.64

1.87

Map2k3

Map Kinase kinase kinase; MAP kinase signaling

Inf2

2.00

2.64

2.00

Nfkb2

NFkB polypeptid 2 (p49/p100); NFkB signaling

inf2

1.32

2.40

1.60

Col5a3

collagen, type V, alpha 3; fibrillar collagen

ECM

4.42

8.40

5.25

Sdc1

syndecan 1; heparan sulfate proteoglycan

ECM

3.54

5.79

3.19

Mmp12

matrix metallopeptidase 12; elastase

ECM2

13.6

33.4

18.2

Mmp19

matrix metallopeptidase 19; degrades aggrecan and COMP

ECM2

5.03

12.9

8.00

Adamts4

ADAMTS 4; degrades proteoglycans

ECM2

2.37

6.21

4.31

Timp1

TIMP metallopeptidase inhibitor 1; known to inhibit MMPs

ECM2

3.58

4.53

3.04

Adamts12

ADAMTS 12; degrades COMP and aggrecan

ECM2

3.14

4.24

3.64

Hyal1

hyaluronoglucosaminidase 1; cleaves hyaluronoglucosamines

ECM2

2.24

3.66

2.37

Arsb

arylsulfatase B; degrades glycosaminoglycan

ECM2

2.82

3.57

2.44

Adamts7

ADAM metallopeptidase; degrades COMP

ECM2

2.46

3.22

2.86

Mmp9

matrix metallopeptidase 9; cleaves Collagen IV and V, fibronectin

ECM2

1.42

3.16

2.50

Adam8

ADAM metallopeptidase domain 8; may cleave extracellular matrix

ECM2

1.95

2.45

1.35

Hyal3

hyaluronoglucosaminidase 3; hyaluronidase

ECM2

1.38

2.23

1.55

Serpine2

serpin peptidase inhibitor, clade E2; inhibits thrombin, trypsin and urokinase

ECM2

1.52

2.01

1.55

Pdgfb

PDGFb polypeptide; chondrogenesis

GF

2.15

4.11

2.92

Csf1r

CSF 1 receptor; for CSF and IL-34, macrophage differentiation

GF

2.94

4.09

2.94

Tgfbr1

TGF b receptor 1; activates SMAD signaling for bone formation

GF

2.45

3.48

2.56

Sfrp4

secreted frizzled-related protein 4; Wnt signaling

GF2

5.50

8.96

6.26

Wnt5a

Wnt family, member 5A; Wnt signaling

GF2

3.65

8.15

6.47

Inhba

inhibin, beta A; TGF-b signaling

GF2

4.43

7.00

4.56
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Table 4. Cont.

Cluster II (430 annotated genes, 305 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA 5

OA 9

OA 21

Igfbp4

IGF binding protein 4; IGF regulation

GF2

4.15

5.34

4.23

Wnt7b

Wnt family, member 7B; Wnt signaling

GF2

1.76

2.77

1.38

Igfbp3

IGF binding protein 3; IGF regulation

GF2

2.33

2.44

2.16

Please see Table 2 for group description. A full list of these genes is given in Table S3.
doi:10.1371/journal.pone.0024320.t004

response evidenced by upregulation of anti-inflammatory genes.
Simultaneously, there is a significant reduction in the suppression
of matrix-associated proteins and growth factors as compared to
cartilage with Grade 1 or Grade 2 damage. Collectively, the
precise modulation of sequential up and down regulation of these
genes may support the cartilage damage observed during the
progression of MIA. Further elucidation of the key molecules that
regulate the expression of catabolic as well as anabolic genes is
critical in understanding the mechanisms of cartilage damage in
experimental and human OA.

pathogen/antigen recognition/clearance (Lbp, Tlr4, Cd14)
[51,52,53]; (iv) ECM for bone formation (Postn, Ogn, Tnn) likely
associated with repair/formation of osteophyte; and (v) antiangiogenic collagens (Col XVIIIa1, -IVa1 -IVa2) and collagens
associated with soft tissue and collagen type 1 (Col XII1a1, -IIIa1,
-Va1), suggesting that these genes may be important in the
replacing damaged cartilage with bone and fibrous tissue in OA
(Figure 1o). In fact, collective upregulation of many of these genes
(Tnn, Postn, Vegf, Vcam1) has also been reported in later stages of
experimental and human OA [10,54,55,56,57,58]. However, it
should be noted that these attempts to remodel seemed to occur
under the influences of damage-associated molecular patterns
(DAMPs) since sustained overexpression of DAMP-related ligand
(Vcan), mediators (Cd14 and Ly96), and signaling receptors (Tlr4
and Tlr7) was observed [59].
Interestingly, the expression of many genes for ECM proteins
(Col2a1, Col10a1, Col9a1, Col9a2, Col9a3, Col27a1, Matn3, Chad, Prelp,
Hapln1, Fbln5, Fbln7, Prg4, Acan, Sdc1, Cilp, Cilp2, Ntn1, Spon2, Eln, Bgn,
Sdc4) was relatively increased in the cartilage with Grade 3–3.5
damage as compared to cartilage with less damage (Grade 1 and 2).
At the same time, gene expression of peptidases involved in matrix
breakdown (Pi15, Chst3, Chst3, Mmp12, Mmp19, Adamts4, Adamts12,
Mmp9, Hyal1, Hyal3, Arsb, Gusb) was relatively downregulated in this
stage as compared to earlier stages. In this respect, earlier studies have
shown that cartilage from later stages of human OA show increased
synthesis of certain matrix proteins in comparison to cartilage from
early OA [10,11,60]. The basis for this increased expression of matrix
associated genes in late stage cartilage degradation (Grade 3–3.5) is as
yet not clear. However, it is likely that lesser suppression of TGF-b1,
Ctgf, and Sox9 as well as antiinflammatory molecules, may support
matrix induction. Additionally, upregulation of gene expression of
bone formation related molecules (Tgfb2, Pdgfc, Pdgfrb, Ogn, Egfr, Ctgf,
Igfbp,Bmp5, Bmpr1a, Fgfr2, Fgfr3, and molecules of Wnt signaling
cascade) in Grade 3–3.5 cartilage damage may also play a role
in the upregulation of matrix genes. Many of these molecules are
also upregulated in cartilage from human OA [11,13,39,41,56,
61,62,63].
In summary, the present study provides evidences that the
progression of cartilage damage is driven by complex but precise
regulation of gene clusters that are induced or suppressed during a
specific stage of cartilage damage (Figure 9). Cartilage with close to
Grade 1 damage exhibited upregulation of genes associated with
acute inflammation and innate immunity, broad specificity
proteases, and cell cycle/division and suppression of genes for
proteoglycan synthesis. Gene expression in cartilage with Grade 2
damage was associated with dynamic upregulation of genes driven
by NF-kB such as inflammatory mediators/cytokines, metallopeptidases, and immune trafficking. Chronic inflammation was
paralleled by suppression of growth factors and collagens.
Cartilage with Grade 3–3.5 damage exhibited an adaptive
PLoS ONE | www.plosone.org

Materials and Methods
Monoiodoacetate-induced arthritis
The work was performed under the protocol number
2009A0138 approved by the Institutional Animal Care and Use
Committee, The Ohio State University. Female Sprague-Dawley
rats, 12–14 weeks old (Harlan Labs, IN) were randomly assigned
to 4 groups (15 rats/group). The right knees of rats were given
intra-articular injection of 50 ml saline in sham controls (Cont,
n = 15), or monoiodoacetate (2 mg/50 ml saline) in experimental
animals to induce MIA (n = 45). Following administration of
monoiodoacetate, the cartilage exhibited Grade 1, Grade 2, or
Grade 3–3.5 on days 5, 9, and 21, respectively. Therefore,
progression of cartilage damage and changes in gene expression
profiles were carried out on day 5 (MIA5; n = 15), day 9 (MIA9;
n = 15), or day 21 (MIA21; n = 15) post-monoiodoacetate injection.
Among them, 5 femurs from each group were snap-frozen in
liquid nitrogen for microarray and real time-Polymerase Chain
Reaction (rt-PCR) analyses (n = 5), and the remaining 10 femurs
were immediately examined macroscopically using a stereomicroscope and then fixed in 10% buffered formalin for microscopic
examination of the cartilage and bone, or mCT imaging to assess
the overall subchondral bone loss.

Macroscopic and microscopic examination
Gross morphologies of femurs were recorded photographically
under a stereomicroscope. The microscopic examination was
performed in paraffin embedded and Hematoxylin-Eosin (H&E)
stained femurs. The cartilage damage was graded according to
Pritzker et al. [9].

MicroCT analysis
To assess the involvement of subchondral bone in MIA, the
femurs were scanned at approximately 19.4 mm resolution on an
Inveon microCT from Siemens Preclinical (Knoxville, TN). The
scans were run as 220 degree half scans with a theta of 0.5 degrees,
with 500 ms exposure, and 700 projections/360 degrees. The
source for the acquisition was run at 80 kV and 500 mA with
12
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Table 5. Suppression of salient genes in cartilage with Grade 2 damage (Cluster V).

Cluster V (417 annotated genes, 274 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA 5

OA 9

OA 21

Cdkn1c

CDK inhibitor 1C (p57); negative regulator of cell proliferation

CD

24.94

25.79

23.44

Pdcd4

programmed cell death 4; inhibits proliferation

CD

22.19

22.90

21.74

Il7

interleukin 7; B and T cell development

Inf

24.40

25.85

24.53

Il16

IL 16; chemoattarctant for immune cells

inf

23.78

24.52

21.68

Il17b

interleukin 17B; Induces TNF-a and IL-1b from monocytic cells

inf

22.84

23.32

22.93

Nrk

Nik related kinase; NF-kB sgnaling

inf2

216.4

218.7

216.2

Matn3

matrilin 3; development and homeostasis of cartilage and bone

ECM

226.3

298.1

274.6

Col10a1

collagen, type X, alpha 1; matrix in hypertrophic cartilage

ECM

229.0

283.3

245.5

Col9a1

collagen, type IX, alpha 1; major cartilage matrix protein

ECM

215.3

277.0

246.1

Col2a1

collagen, type II, alpha 1; major cartilage matrix protein

ECM

214.9

250.3

29.06

Chad

Chondroadherin; chondro & osteoblasts integrin a2b1

ECM

218.3

232.6

27.10

Col9a2

collagen, type IX, alpha 2; major cartilage matrix protein

ECM

213.5

227.6

222.4

Scin

scinderin; cellular protein involved in exocytosis

ECM

222.2

224.4

211.7

Hapln1

hyaluronan and proteoglycan link prot 1; binds to aggregates of proteoglycan
monomers with hyaluronic acid

ECM

211.0

219.0

27.54

Col9a3

collagen, type IX, alpha 3; major cartilage matrix protein

ECM

29.38

218.9

212.6

Col11a2

collagen, type XI, alpha 2; major cartilage matrix protein

ECM

26.29

216.9

29.94

Vit

vitrin; promotes matrix assembly and cell adhesiveness

ECM

213.4

215.1

210.9

Prg4

proteoglycan 4; major cartilage matrix protein

ECM

27.61

27.65

23.52

Col11a1

collagen, type XI, alpha 1; major cartilage matrix protein

ECM

23.77

25.71

22.98

Mgp

matrix Gla protein; associated with cartilage and bone matrix

ECM

24.72

25.63

23.28

Matn1

matrilin 1; major cartilage matrix protein

ECM

23.86

24.00

23.97

Fbln5

fibulin 5; promote adhesion of endothelial cells

ECM

22.54

23.08

21.66

Col24a1

collagen, type XXIV, alpha 1; regulate Col type I

ECM

21.97

22.51

21.51

Col5a3

collagen, type V, alpha 3; fibrillar collagen

ECM

21.82

22.34

21.79

Hs3st1

heparan sulfate 3-O-sulfotransferase 1;heparin sulfate synthesis

ECM 2

26.09

26.25

27.69

Adamts3

ADAMTS 3; cleavage of propeptide of type II collagen

ECM 2

23.32

23.91

24.69

Adamts6

ADAMTS 6; likely a metallopeptidase

ECM 2

22.15

23.05

22.36

Alpl

alkaline phosphatase; matrix mineralization

ECM 2

22.80

22.83

21.26

Chsy3

chondroitin sulfate synthase 3; chondroitin synthesis

ECM 2

22.58

22.61

22.06

Has2

hyaluronan synthase 2; hyaluran synthesis

ECM 2

21.66

22.29

23.28

Mmp16

matrix metallopeptidase 16; membrane type MMP-3

ECM 2

21.38

22.20

21.13

Omd

osteomodulin; likely role in mineralization

GF

211.5

213.0

23.35

Fgfr3

fibroblast growth factor receptor 3; cell growth in wound healing

GF

25.67

27.94

25.77

Fgfr2

fibroblast growth factor receptor 2; cell growth in wound healing

GF

22.77

25.61

23.06

Ctgf

connective tissue growth factor; chondrocyte prolifer and differentia

GF

22.79

25.24

21.68

Bmp5

bone morphogenetic protein 5; cartilage and bone formation

GF

22.50

24.75

22.60

Ghr

growth hormone receptor; bone growth

GF

23.19

24.24

22.37

Tgfbr3

transforming growth factor, b receptor III; Smad activation

GF

22.32

23.55

21.74

Bmp3

BMP 3; antagonizes BMPs in bone formation

GF

21.12

23.34

21.36

Igfbp5

insulin-like growth factor binding prot 5; promote growth by IGF

GF

22.29

23.04

21.33

Vdr

vitamin D3 recp; Ca++ homeostasis

GF

21.21

22.72

22.78

Tgfb3

TGFb3; chondrocyte div and differentiation

GF

21.75

22.65

21.25

Bmpr1a

BMP receptor, type IA; Smad transcriptional activation

GF

22.01

22.46

21.53

Egf

epidermal growth factor (b-urogastrone); mitogenic involved in cell

GF

22.11

22.37

22.04

Frzb

frizzled-related protein; cartilage and bone development

GF2

247.4

252.7

249.6

Ptch1

patched homolog 1; receptor for Ihh

GF2

29.85

216.1

27.60

Wif1

WNT inhibitory factor 1; inhibits Wnt proteins

GF2

213.0

215.2

26.43
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Table 5. Cont.

Cluster V (417 annotated genes, 274 genes in IPA database)
Gene

Fold change

Description and Function

Group

OA 5

OA 9

OA 21

Sfrp5

secreted frizzled-related protein 5; Wnts regulation, growth

GF2

29.76

211.8

211.4

Fzd9

frizzled homolog 9; receptor for Wnts regulates bcatenin pathway

GF2

28.61

28.90

26.65

Sox6

SRY (sex determining region Y)-box 6; role in skeleton formation

GF2

23.91

25.87

23.02

Ihh

Indian hedgehog; endochondral ossification bone growth ossificatic

GF2

24.63

25.24

24.05

Wisp3

WNT1 inducible signal protein 3; Wnt regulation growth & different

GF2

23.69

23.91

23.73

Dlx5

distal-less homeobox 5; chondrogenesis and osteoblastogenesis

GF2

22.52

23.73

22.46

Please see Table 2 for group description. A full list of these genes is given in Table S4.
doi:10.1371/journal.pone.0024320.t005

0.5 mm of Al filtration for beam hardening. Analysis of images
was conducted on an Inveon Research Workstation.

eligible genes/molecules in the data set at a given time point.
The significance value and network score were based on the
hypergeometric distribution and calculated with the right-tailed
Fisher’s exact test. The network score was the negative log of
the p value.

RNA extraction and microarray analysis
The cartilage from the distal end of individual femur (10–
15 mg/femur) was examined under a stereomicroscope (Zeiss,
Germany). Superficial articular cartilage on the patellar and
condylar surfaces of the distal ends of femur was chipped off in a
frozen state, avoiding the areas immediately around lesions. The
cartilage chips from each knee were collected separately, and
pulverized into 1 mm fragments in a Mikrodismembrator S
(Sartorious, France) at 2500 rpm for 30 seconds [32]. RNA was
extracted with Trizol reagent (Invitrogen, CA), and each sample of
RNA was analyzed in a 2100 Bioanalyzer (Agilent, CA) to ensure
optimal quality of RNA [64].
A total of 300 ng of RNA was used for cDNA synthesis and
labeling using Whole Transcript (WT) cDNA Synthesis and
Amplification Kit, and WT Terminal Labeling Kit (Affymetrix,
CA). The labeled samples were hybridized on Affymetrix
GeneChip Rat Gene 1.0 ST Array and scanned at the Microarray
Shared Resource Facility at the OSU Comprehensive Cancer
Center.
The intensity scans from three biologically independent arrays
per treatment were subjected to gene expression analysis using
Partek Genomic Suite version 6.4 (Partek Inc., MO). The
significance of differences among the conditions was calculated
by the analysis of variance (ANOVA) and only significantly
regulated transcripts (p,0.05) were considered for further
analyses. Variations among the samples in each condition were
examined by principal components analysis (PCA), and subjected
to both hierarchical and partition clustering by Partek Genomic
Suite. All data is MIAME compliant and the raw data has been
deposited in a MIAME compliant database GEO (accession
number GSE28958).

Expression of selected genes from clustering analysis was confirmed
by rt-PCR as previously described [65]. Briefly, extracted RNA was
subjected to first strand cDNA synthesis using the Superscript III
Reverse Transcriptase Kit (Invitrogen, CA). Gene expression was
assessed by amplifying the cDNA with custom-designed primers in the
iCycler iQ Real-Time PCR System (Bio-Rad, CA). The primers used
were: Rps18-sense 59-GCGGCGGAAAATAGCCTTCG-39, antisense 59-GGCCAGTGGTCTTGGTGTGCTG-39; Ctss-sense 59AAATCGAGCTGCCACGTGTT-39, anti-sense 59-TGGCCACTGCTTCTTTCAGAG-39; Il-1b-sense 59-TATGTCTTGCCCGTGGAGCTT-39, anti-sense 59-TAGCAGGTCGTCATCATCCCA39; Mmp12-sense 59-CCAGGAAATGCAGCAGTTCTTT-39; antisense 59-GCTGTACATCAGGCACTCCACAT-39; Ccr1-sense 59TCAGTGTGAGCAGAGCAAGCA-39, anti-sense 59-CCGCTCACCCACAAAGACATA-39; Alox5-sense 59-TTCTCCGCACACATCTGGTGT-39, anti-sense 59-GGCAATGGTGAACCTCACATG39; Vcam1-sense 59-GCCGGTCATGGTCAAGTGTTT-39, antisense 59-CATGAGACGGTCACCCTTGAA-39; Cilp-sense 59-TGTGAAGTCCAAGGTCACCCA-39, anti-sense 59-GTAGAAGGAGTTGGTGGCATTCTG-39; Sox9-sense 59-ATCTGAAGAAGGAGAGCGAG-39; anti-sense 59-CAAGCTCTGGAGACTGCTGA39; Col9a1-sense 59-TGATGGCTTTGCTGTGCTG-39, anti-sense
59-TGACTGGCAGTTCATGGCA-39; Col2a1-sense 59-ATGAGGGCCGAGGGCAACAG-39, anti-sense 59-GATGTCCATGGGTGCAATGTCAA-39.

Functional gene network analysis

Statistical Analysis

The gene expression data derived from microarray analysis
was used to generate functional and molecular networks
through the use of IPA (Ingenuity Systems, CA). A fold-change
cutoff of 2.0 was set to identify and assign the molecules to the
Ingenuity’s Knowledge Base. In these analyses, gene expression
changes were considered in the context of physical, transcriptional or enzymatic interactions of the gene/gene products, and
then grouped according to interacting gene networks at a
particular point. The score assigned to any given gene network
took into account the total number of molecules in the data set,
the size of the network and the number of assigned network

All time dependent analyses were performed on 15 animals
per group. Microarray analyses were performed on cartilage
extracted from three separate animals. The significance among
the conditions in the microarray data was tested by Partek
Genomic suite by ANOVA to render significantly regulated
genes (p,0.05) during the progression of MIA at each time
point. ANOVA with Tukey’s HSD post hoc test by SPSS v 17
was used to determine the significance levels of rt-PCR data that
include two additional independent samples per group to
microarray-examined specimens (n = 5). p,0.05 was regarded
as significant.
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Table 6. Induction of salient genes in cartilage with Grade 3–3.5 damage (Cluster III).

Cluster III (391 annotated genes, 271 genes in IPA database)

Fold change

Gene

Description and Function

Group

OA 5

OA 9

OA 21

Ccnd1

cyclin D1; cell cycle control

CD

2.28

2.22

2.72

Cdkn1a

cyclin-dependent kinase inhibitor 1A; inhibits cell division

CD

1.10

1.95

2.56

Pawr

PRKC, apoptosis, WT1, regulator; proapoptotic

CD

1.71

1.98

2.44

Klf10

Kruppel-like factor 10; transcriptional repressor of cell growth

CD

1.36

2.60

2.42

Cxcl13

chemokine (C-X-C motif) ligand 13; chemotactic for B-lymphocytes

Inf

1.64

2.10

2.98

Il10rb

interleukin 10 receptor, beta; anti-inflamamtory

Inf

2.14

2.40

2.81

Il15

interleukin 15; proliferation of T-lymphocytes

Inf

1.26

1.48

2.01

Cdh13

cadherin 13, H-cadherin (heart); cell-cell adhesion glycoprotein

Inf2

1.46

4.63

8.59

Lilbr4

leukocyte IgG-like receptor, subfam B, mem4; controls inflammation

Inf2

7.33

6.00

7.00

Lbp

LPS binding protein; binds LPS to present it to TLR4 and CD14

Inf2

1.66

3.65

4.45

F3

coagulation factor III; initiates coagulation cascade with Factor VII

Inf2

2.05

2.56

3.14

Lpl

lipoprotein lipase; cleaves triglycerides

Inf2

1.36

1.58

2.91

Alox5

arachidonate 5-lipoxygenase; catalyzes leukotriene synthesis

Inf2

1.82

1.61

2.86

Tlr4

toll-like receptor 4; LPS receptor

Inf2

2.14

1.83

2.85

Vcam1

vascular cell adhesion molecule 1; immune response

Inf2

2.69

1.82

2.61

Ptges

prostaglandin E synthase; prostaglandin synthesis, inflammatory responses, pain
perception

Inf2

1.40

2.34

2.60

Pld2

phospholipase D2; cleaves phosphatidyl choline

Inf2

1.72

2.32

2.49

Socs3

suppressor of cytokine signaling 3; negative regulator of inflammatory response

Inf2

1.69

2.09

2.47

Nfkbia

NF-kB inhibitor, alpha; inhibitor of NF-kB- IkBa

Inf2

1.42

2.45

2.17

Tnn

tenascin N; cartilage and bone formation

ECM

15.5

18.8

20.9

Postn

periostin; osteoblast specific factor; cell adhesion, mineralization

ECM

5.88

5.05

7.23

Lum

lumican; collagen fibril organization

ECM

4.09

5.03

5.90

Col18a1

collagen type XVIII a1; a potent antiangiogenic

ECM

2.71

3.92

5.66

Col4a1

collagen type IV a1; inhibits endothelial proliferation/angiogenesis

ECM

1.80

3.03

4.33

Col3a1

collagen type III a1; soft tissue associated with Collagen type 1

ECM

2.02

3.19

3.88

Col12a1

collagen type XII, a1; fibrillar collagen

ECM

2.10

3.11

3.42

Col4a2

collagen type IV a2; inhibits endothelial proliferation/angiogenesis

ECM

1.39

2.12

3.13

Col6a3

collagen, type VI, alpha 3; linkage of matrix/cell

ECM

1.30

2.42

2.71

Col5a1

collagen, type V, alpha 1; fibrillar collagen

ECM

1.10

1.73

2.12

Adam23

ADAM metallopeptidase domain 23; nonproteolytic metalloprotease, cell-cell
adhesion

ECM2

3.97

3.56

5.50

Serpine1

serpin peptidase inhibitor, clade E1; inhibits plasminogen activator

ECM2

3.27

3.88

4.81

Timp2

TIMP metallopeptidase inhibitor 2; inhibitor of several MMPs

ECM2

1.38

2.19

3.07

Mmp14

matrix metallopeptidase 14; activates progelatinase

ECM2

1.95

3.29

3.01

Mmp2

MMP 2; ECM breakdown in normal physiologic processes

ECM2

1.01

1.99

2.84

Mmp11

matrix metallopeptidase 11; matrix remodeling, vascular invasion

ECM2

1.11

1.47

2.39

Adamts2

ADAMTS 2; cleaves tissue propeptides of collagen type I and II

ECM2

1.28

1.62

2.37

Ctsd

cathepsin D; intracellular proteinase inhibitor

ECM2

1.61

2.3

2.25

Tgfb2

TGF beta 2; cell division and growth differentiation

GF

1.26

2.67

2.63

Pdgfrb

PDGF receptor, b polypeptide; angiogenesis, cell proliferation and differentiation

GF

1.18

1.77

2.46

Osmr

oncostatin M receptor; increases cartilage degradation

GF

1.85

2.41

2.45

Pdgfc

PDGF C; wound healing, proliferation and remodeling

GF

1.04

2.22

2.15

Ogn

osteoglycin; Induces bone formation with TGF-beta-1 or TGF-beta-2

GF

1.22

1.19

2.06

Egfr

epidermal growth factor receptor; cell growth/differentiation

GF

1.29

1.17

2.05

Wisp2

WNT1 inducible signaling protein 2; bone turnover

GF2

2.65

5.71

6.08

Please see Table 2 for group description. A full list of these genes is given in Table S5.
doi:10.1371/journal.pone.0024320.t006
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Figure 6. Molecular networks generated from the genes in each cluster by Ingenuity Pathways Analysis. The molecular networks
generated from genes in: (A) Cartilage with Grade 1 damage (Cluster I) – Immunological disease network, showing upregulation of genes associated
with acute/innate immune response; (B) Cartilage with Grade 1 damage (Clusters IV) - Skeletal & muscular development and function network,
showing downregulation of transcription factors and growth factors associated with matrix synthesis. The symbols under individual mediators are
defined in Figure 8B. Red, green, and white colors represent upregulation, downregulation and no regulation as compared to cont cartilage,
respectively. The shading of each color represents fold change in gene expression; dark, higher changes and light lower changes.
doi:10.1371/journal.pone.0024320.g006

Figure 7. Molecular networks generated from the genes in each cluster by Ingenuity Pathways Analysis. The molecular networks
generated from genes in: (A) Cartilage with Grade 2 damage (Cluster II) – Inflammatory response/Immune cell trafficking network, showing
upregulation of genes associated with chronic inflammation and immune cell trafficking; (B) Cartilage with Grade 2 damage (Clusters V) – Skeletal and
muscular disease network showing suppression of genes for growth factors and major matrix proteins. The symbols under individual mediators are
defined in Figure 8B. Red, green, and white colors represent upregulation, downregulation and no regulation as compared to cont cartilage,
respectively. The shading of each color represents fold change in gene expression; dark, higher changes and light lower changes.
doi:10.1371/journal.pone.0024320.g007
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Figure 8. Molecular networks generated from the genes in each cluster by Ingenuity Pathways Analysis. The molecular networks
generated from genes in: (A) Cartilage with Grade 3–3.5 damage (Cluster III) - Inflammatory disease network showing upregulation of many genes
involved in immune suppression and adaptation. Each cluster is based on the genes that were significantly up or downregulated (p,0.05, over 62fold change) in articular cartilage from Cont, MIA5, MIA9, and MIA21 specimens. The symbols under individual mediators are defined in (B). Red, green,
and white colors represent upregulation, downregulation and no regulation as compared to cont cartilage, respectively. The shading of each color
represents fold change in gene expression; dark, higher changes and light lower changes.
doi:10.1371/journal.pone.0024320.g008

Figure 9. Schematic presentation of collective catabolic and anabolic gene regulation during the progression of MIA. Grade 1
damage in the cartilage was associated with induction of genes required for acute inflammation and innate immunity, broad specificity proteases,
and cell cycle/division and suppression of genes for proteoglycan synthesis. Grade 2 damage in the cartilage was associated with induction of gene
for NF-kB signaling cascade, inflammatory mediators/cytokines, metallopeptidases, and immune trafficking, and suppression of growth factors and
collagens. Grade 3–3.5 damage in the cartilage exhibited upregulation of anti-inflammatory genes, and simultaneous reduction in the suppression of
matrix-associated proteins and growth factors as compared to cartilage with Grade 1 or Grade 2 damage. Collective and sequential up and down
regulation of these gens may be important in the cartilage damage during the progression of MIA.
doi:10.1371/journal.pone.0024320.g009
PLoS ONE | www.plosone.org
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Table S3 Changes in the expression of genes in Cluster
II. Please see Table S1 for group description.
(DOC)
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expression of significant number of genes associated with cell
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